Abstract PS2-07: Intrinsic Subtype at Progression to CDK4/6 Inhibitors Plus Endocrine Therapy in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer (MBC)Isabel García-Fructuoso, Francesco Schettini, Oleguer Castillo et al.|Clinical Cancer Research|2025Cited by 3
Endocrine-based strategies after CDK4/6 inhibitors in biomarker-selected subgroup of hormone receptor positive advanced breast cancer: A systematic review and network meta-analysisAdela Escudero, Guillermo Villacampa, Meritxell Bellet et al.|Cancer Treatment Reviews|2025Cited by 3
Abstract P2-05-18: Molecular effects of short pre-operative endocrine therapy in hormone receptor-positive and HER2-negative early breast cancerRaquel Gómez Bravo, Fara Brasó‐Maristany, Bárbara Adamo et al.|Clinical Cancer Research|2025Cited by 0